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Objective: To compare the effectiveness of ondansetron and prochlorperazine to treat vomiting. 
Secondary objectives were the effectiveness of ondansetron and prochlorperazine to treat nausea 
and their tolerability.
Methods: This was a prospective, randomized, active controlled, double-blinded study. Using a 
convenience sample, patients were randomized to either intravenous ondansetron 4mg (n=32) or 
prochlorperazine 10mg (n=32). The primary outcome was the percentage of patients with vomiting 
at 0-30, 31-60, and 61-120 minutes after the administration of ondansetron or prochlorperazine. 
Secondary outcomes were nausea assessed by a visual analog scale (VAS) at baseline, 0-30, 
31-60, and 61-120 minutes after the administration of ondansetron or prochlorperazine and the 
percentage of patients with adverse effects (sedation, headache, akathisia, dystonia) to either drug. 
We performed statistical analyses on the VAS scales at each time point and did a subgroup analysis 
to examine if nausea scores were affected if the patient had vomited at baseline. 
Results: The primary identified cause for nausea and vomiting was flu-like illness or gastroenteritis 
(19%). The number of patients experiencing breakthrough vomiting at 0-30, 31-60, and 61-120 
minutes was similar between groups for these time periods; however, more patients receiving 
ondansetron experienced vomiting overall (7 [22%] vs. 2[3.2%] patients,  p=not significant). Nausea 
scores at baseline and 0-30 minutes were severe and similar between groups; however, at 31-60 
and 61-120 minutes, patients receiving prochlorperazine had better control of nausea (24.9 vs. 43.7 
mm, p=0.03; 16.8 vs. 34.3 mm, p=0.05). Sedation scores were similar between groups. There were 
no cases of extrapyramidal symptoms as assessed by the treating physician and there were four 
cases of akathisia (prochlorperazine=3 [9%], ondansetron=1[3%]).
Conclusion: Prochlorperazine and ondansetron appear to be equally effective at treating vomiting in 
the emergency department. [West J Emerg Med. 2011;12(1):1-5.]
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INTRODUCTION
Nausea  and  vomiting  are  common  symptoms  in  the 
emergency department (ED). Antiemetic agents used to treat 
nausea  and  vomiting  include  phenothiazine  derivatives, 
prokinetic agents and 5-HT3 receptor antagonists. No agent is 
used uniformly for nausea and vomiting in the ED and recent 
studies  include  comparisons  to  ondansetron.1-8  This  study 
compared prochlorperazine to ondansetron for the treatment of 
nausea and vomiting in the ED.
BACKGROUND
Chemical mediators involved in nausea and vomiting 
include dopamine, serotonin, histamine, norepinephrine and 
glutamine.9-11 These substances activate the chemoreceptor 
trigger zone (CTZ), found in the area postrema of the fourth 
ventricle. The CTZ then stimulates the vomiting center, which 
initiates the act of vomiting. The activation of 5-HT3 in the 
gastrointestinal (GI) tract can initiate vomiting by activating 
the vomiting center. Prochlorperazine and promethazine Western Journal of Emergency Medicine  2  Volume XII, no. 1  :  February 2011
are phenothiazine antiemetics that have been used for the 
treatment of nausea and vomiting secondary to a wide range of 
pathologies. Their primary mechanism of action is antagonism 
of D2 receptors in the CTZ, although phenothiazines also 
have antihistaminic and anticholinergic properties. The 5-HT3 
antagonist ondansetron blocks serotonin in the CTZ and the 
gastrointestinal tract. Ondansetron has been examined in over 
100 studies for the treatment of nausea and vomiting related to 
chemotherapy and anesthesia.10 There are limited data on the 
use of ondansetron in the ED, except for use in children.1,2 
METHODS
This was a prospective, randomized, active controlled, 
double-blinded study designed to compare the effectiveness 
of ondansetron and prochlorperazine to treat vomiting. 
Secondary objectives included the effectiveness of 
ondansetron and prochlorperazine to treat nausea and the 
tolerability of prochlorperazine and ondansetron in patients 
with nausea and/or vomiting. Patients were eligible for 
inclusion if they were admitted to the ED with nausea and/
or vomiting. Exclusion criteria included: previous treatment 
in the ED with antiemetics; missed last menstrual period or 
pregnancy; less than 18-years-old; conditions with impaired 
GI tract function (i.e. irritable bowel syndrome); impaired 
mental status; treatment with antineoplastic agents within 
seven days prior to randomization; patients unable to read, 
write, or communicate in the English language; patients 
leaving the ED against medical advice. Patients were assigned 
to treatment using a 1:1 random numbers table to 4mg of 
ondansetron intravenous (IV) push over 2-5 minutes, or 10 mg 
of prochlorperazine IV administered over two minutes.
Information collected on admission included: 
demographics, past medical history, social history, chief 
complaint, suspected cause of nausea and/or vomiting, number 
of episodes of vomiting prior to randomization, medications 
prior to admission and during study time period, duration of 
nausea and/or vomiting (per history), number of episodes of 
vomiting, and number of dry heave episodes. The presence 
or absence of extrapyramidal symptoms or akathisia was 
assessed by physician observation, and no scale or specific 
criteria were used to rate severity.
Study Outcomes
The primary outcome was the percentage of patients with 
vomiting at 0-30 minutes, 31-60 minutes and 61-120 minutes 
after the administration of ondansetron or prochlorperazine. 
Secondary outcomes included: nausea assessed by a VAS 
at baseline and three time intervals, 0-30 minutes, 31-60 
minutes and 61-120 minutes, based on similar methods by 
Ernst et al5. We measured VAS scores from 0 to 100 mm 
with zero being no nausea and 100 mm the worst possible 
score. In addition, we stratified VAS scores into quartile 
ranges (none, mild, moderate and severe) to aid in the clinical 
application of the numerical data. Other outcomes included 
the percentage of patients experiencing adverse effects 
(sedation, headache, akathisia and dystonia) to ondansetron or 
prochlorperazine and treatment failures, defined as requiring 
rescue antiemetic treatment >30 minutes after administration 
of the study medication. We also assessed sedation and 
headache by a VAS with scores from 0 to 100 mm (none to 
most severe) and stratified them into quartile ranges (none, 
mild, moderate, severe). The need for a rescue treatment was 
based on physician preference. Rescue medications were 
not administered ≤30 minutes post administration of study 
medication.  The decision to administer a rescue medication, 
as well as the medication choice, was up to the discretion of 
the treating physician and patients were not crossed over to the 
other treatment group. Blinding could be broken if there was a 
safety concern; however, this was not required in any patients.
RESULTS
Three hundred fifty-three patients were screened and 64 
patients were randomly assigned to either ondansetron or 
prochlorperazine. Reasons for exclusion consisted of: received 
prior treatment (38%), refused to participate (19%), history of 
impaired GI tract function (9%), altered mental status (7%), 
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Table 1. Baseline characteristics
Prochlorperazine 
n=32
Ondansetron
n=32
p-value
Age* 41 40 0.50
Female‡ 53% 56% 1.00
African-American‡ 91% 87% 1.00
Disposition: discharged‡ 94% 74% 1.00
Duration of nausea and vomiting 
(hours)*
186 77 0.09
Vomiting in the emergency department 38% 19% 0.99
Chief complaint: nausea and vomiting‡ 69% 50% 1.00
p-values based on *students t-test or ‡chi-squaredVolume XII, no. 1  :  February 2011  3  Western Journal of Emergency Medicine
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Table 2. Proportion of patients in each treatment group with vomiting at 0 to 30, 31 to 60, and 61 to 120 minutes after administration of 
treatment, in all patients and according to the presence/absence of vomiting at baseline
Proportion (%) 
with vomiting at 
0-30 minutes
p-value Proportion (%) 
with vomiting at 
31-60 minutes
p-value Proportion (%) 
with vomiting at 
61-120 minutes
p-value
All patients
0.49 1.00 0.36
Prochlorperazine 0/32 (0.0%) 1/32 (3.2%) 1/28 (3.6%)
Ondansetron 2/32 (6/3%) 1/32 (3.1%) 4/32 (12.5%)
Patients with no vomiting 
at baseline
Prochlorperazine 0/20 (0.0%)
1.00
0/19 (0.0%)
1.00
1/19 (5.3%)
1.00
Ondansetron 0/25 (0.0%) 0/25 (0/0%) 2/25 (8.0%)
Patients with vomiting at 
baseline
Prochlorperazine 0/10 (0.0%)
0.13
1/10 (10.0%)
1.00
0/7 (0.0%)
0.19 Ondansetron 2/6 (33.3%) 1/6 (16.7%) 2/6 (33.3%)
p-values are based on Fisher’s Exact Test
GI bleed (5%), unable to obtain IV access (3%), and unable to 
consent (19%). The primary cause for nausea and vomiting 
was flu-like illness or gastroenteritis (19%); other causes 
included hyperglycemia (6%), alcohol intoxication (5%), 
gastritis (5%), adhesions (3%), cholecystitis (3%), pancreatitis 
(2%), renal colic (2%), or undetermined (55%). Demographics 
for the study population are listed in Table 1. The number of 
patients experiencing breakthrough vomiting at 0-30 minutes, 
31-60 minutes and 61-120 minutes is shown in Table 2. 
Results were similar between groups; however, overall more 
patients receiving ondansetron experienced breakthrough 
vomiting [7 (22%) vs. 2 (6.2%) patients, p=0.23]. In addition, 
one patient randomized to prochlorperazine, and five patients 
in the ondansetron group required rescue treatment during the 
study time period (p=0.20). One patient in the 
prochlorperazine group and four in the ondansetron group 
received 25mg promethazine IV, and one patient in the 
ondansetron group received metoclopramide 10mg IV. Results 
for nausea VAS scores are in Table 3; they were divided into 
four categories: none (0), mild (1-33), moderate (34-66) and 
severe (>66). Nausea scores at baseline and 0-30 minutes were 
severe and similar between groups, however at 31-60 and 
61-120 minutes, patients receiving prochlorperazine had 
significantly lower nausea scores; the prochlorperazine group 
scores were mild and the ondansetron were moderate at 
61-120 min. In a subgroup analysis, there was no difference in 
nausea scores if the patient had vomited at baseline. Data for 
the VAS was not complete for all subjects at all time points 
due to the inability to perform the VAS secondary to increased 
sedation (prochlorperazine 7 [22%], ondansetron 5 [16%]), or 
dropouts due to receiving rescue treatment (prochlorperazone 
1 [3%], ondansetron 5 [16%]). Sedation scores were mild for 
both groups throughout the study period and not statistically 
different between groups, (p>0.05). Headache scores were 
mild in the prochlorperazine group at all time points, while 
moderate at baseline and 0-30 min and mild at 31-60 and 
61-120 minutes with ondansetron. Headache scores were 
significantly lower in the prochlorperazine group at all times 
points, (p<0.05). There were no cases of extrapyramidal 
symptoms and four cases of akathisia (prochlorperazine=3 
[9%], ondansetron=1[3%]).
DISCUSSION
These results demonstrate that prochlorperazine and 
ondansetron appear to be equally effective at controlling 
vomiting in patients presenting to the ED with nausea and/or 
vomiting. Theoretically prochlorperazine may have an 
advantage over ondansetron, as serotonin can cause the release 
of dopamine.12,13 If dopamine is already present, or released, 
during nausea or vomiting, blocking serotonin will not be able 
to prevent the action of this dopamine. Although the results 
were not statistically different, this may explain the improved 
response with prochlorperazine. Central 5-HT3 activity may be 
more associated with nausea considering the benefit of 
ondansetron in the pre-treatment of nausea associated with 
chemotherapy and anesthesia, while receptors in the GI tract 
are important with treatment of emergent vomiting. 
When examining the data on antiemetics in the ED, 
prochlorperazine and promethazine were studied in a 
randomized double-blind comparison of adults with gastritis Western Journal of Emergency Medicine  4  Volume XII, no. 1  :  February 2011
or gastroenteritis. Patients were well-matched according to 
gender, age, duration and number of times vomiting, and 
baseline nausea as determined by a VAS. Eighty-four patients 
were randomized to IV prochlorperazine 10mg (n=42) or 
promethazine 25mg (n=42). Patients were then assessed 
at 30 minutes, 60 minutes and >60 minutes. The results 
showed that in the prochlorperazine group more patients 
demonstrated complete relief (determined by patients) within 
30 minutes when compared to promethazine (33.4% vs. 
16.7%, p=0.021). Results were 50 vs. 47.6% (30 to 60 min) 
and 16.7 vs. 35.7% (>60 minutes), with prochlorperazine 
and promethazine respectively. In addition, there were 
more treatment failures with promethazine compared to 
prochlorperazine, 13 vs. 4 patients (p=0.03). Two studies 
examined the effects of ondansetron compared to placebo 
in primarily pediatric patients admitted to the ED with acute 
gastroenteritis.1,2 In the first study (N=107) IV ondansetron 
resulted in complete cessation of vomiting more often 
compared to placebo (70% vs. 51%, p=0.04) during ED stay.1 
Oral ondansetron was compared to placebo in 145 patients 
in the second study.2 During the ED stay, 87% of patients in 
the ondansetron group and 64% of patients in the placebo 
group experienced no emesis (p=0.004). Follow up at 24 
and 48 hours showed no difference between groups in the 
number of episodes of emesis, or proportion of patients with 
emesis. Recently, ondansetron was compared to promethazine 
in the ED. One hundred twenty patients were randomly 
assigned to ondansetron 4mg or promethazine 25mg IV; those 
receiving prior antiemetics were excluded.8 Ondansetron 
and promethazine were found to be comparable, -34 mm 
vs. -36 mm, respectively, using a 100-mm VAS. In addition 
promethazine caused more sedation and there were two cases 
of akathisia in the promethazine group.
LIMITATIONS
Although this study had a strong design there were 
several limitations. Because we used a convenience sample 
with a small sample size the results of this study would need 
to be confirmed in a larger, powered study. We calculated 
a sample size of 300 patients would be needed to detect a 
30% difference in vomiting between groups with a beta of 
0.8 and an alpha of 0.05, estimating a 70% effectiveness rate 
with ondansetron. With a larger study a smaller, yet clinically 
important, difference in effectiveness may be determined. In 
addition, a higher percentage of patients in the ondansetron 
group (26 vs. 7%) were admitted to the hospital. These 
Ondansetron Versus Prochlorperazine for Nausea and Vomiting  Patka et al.
Table 3. Nausea visual analog scale scores for each treatment group, according to time and presence/absence of vomiting at baseline
All Patients Nausea 
score at 0 
minutes
p-value Nausea score 
at 0-30 minutes
p-value Nausea 
score at 31-
60 minutes
p-value Nausea 
score at 61-
120 minutes
p-value
Prochlorperazine 78.6 ± 28.5 
(n=32)
0.75
47.5 ±33.3 
(n=29
0.73
24.9 ±31.8 
(n=30)
0.03
16.8 ±29.1 
(n=25)
0.05
Ondansetron 72.4 ± 25.6 
(n=32)
50.4 ±33.0 
(n=30)
43.7 ±33.5 
(n=28)
34.3 ±31.7 
(n=26)
Patients with 
no vomiting at 
baseline
Prochlorperazine 70.1 ± 29.9 
(n=20) 0.90
44.2 ±32.4 
(n=17) 0.73
23.8 ±31.0 
(n=18) 0.05
13.4 ±27.5 
(n=16) 0.03
Ondansetron 71.1 ± 22.7 
(n=25)
47.7 ±30.8 
(n=23)
44.4 ±33.7 
(n=21)
37.0 ±32.5 
(n=21)
Patients with 
vomiting at base-
line
Prochlorperazine 88.1 ± 16.4 
(n=10)
0.93
50.9 ±38.2 
(n=10)
0.38
28.4 ±36.6 
(n=10)
0.32
29.0 ±35.0 
(n=7)
0.93
Ondansetron 88.8 ± 17.0 
(n=6)
68.5 ±32.1 
(n=6)
47.3 ±35.1 
(n=6)
27.3 ±31.1 
(n=4)
Note: Visual analog scale scores in table are mean ± standard deviation. p-values are based on ANOVAVolume XII, no. 1  :  February 2011  5  Western Journal of Emergency Medicine
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patients could potentially be considered at higher risk for 
nausea and vomiting due to a greater severity of illness and 
therefore explain the decreased response to ondansetron. 
All patients were not able to participate in post-treatment 
assessment VAS scores due to sedation, which reduced the 
sample size at each time interval. Headache scores were 
significantly lower in the prochlorperazine group; however, 
they were also significantly lower at baseline. The differences 
in scores at baseline could explain the lower headache scores 
overall in the prochlorperazine group. In this study 4mg 
of IV ondansetron was used, which is the dose typically 
used for nausea and vomiting at our institution. However, 
higher and lower doses of ondansetron have been shown to 
be effective.14,15 If a higher dose of ondansetron had been 
used there could have been improved control of nausea and 
vomiting with ondansetron compared to prochlorperazine. 
Finally, our rates of extrapyramidal symptoms or akathisia 
were low; however, physician self-reporting determined their 
presence. If a specific scale was used to detect extrapyramidal 
symptoms or akathisia their rates may have been higher than 
we reported.16
CONCLUSION
Prochlorperazine and ondansetron appear to be equally 
effective to treat vomiting in the ED. Prochlorperazine may 
be more effective in controlling nausea. Although this was a 
prospective, randomized, active controlled, double-blinded 
study, it had a small sample size and the results should be 
confirmed in a larger, powered study.
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